64 results on '"Goyanes, Alvaro"'
Search Results
2. Innovations in Chewable Formulations: The Novelty and Applications of 3D Printing in Drug Product Design.
- Author
-
Rodríguez-Pombo, Lucía, Awad, Atheer, Basit, Abdul W., Alvarez-Lorenzo, Carmen, and Goyanes, Alvaro
- Subjects
DRUG design ,THREE-dimensional printing ,PRODUCT design ,TECHNOLOGICAL innovations ,PATIENT compliance ,VETERINARY drugs - Abstract
Since their introduction, chewable dosage forms have gained traction due to their ability to facilitate swallowing, especially in paediatric, geriatric and dysphagia patients. Their benefits stretch beyond human use to also include veterinary applications, improving administration and palatability in different animal species. Despite their advantages, current chewable formulations do not account for individualised dosing and palatability preferences. In light of this, three-dimensional (3D) printing, and in particular the semi-solid extrusion technology, has been suggested as a novel manufacturing method for producing customised chewable dosage forms. This advanced approach offers flexibility for selecting patient-specific doses, excipients, and organoleptic properties, which are critical for ensuring efficacy, safety and adherence to the treatment. This review provides an overview of the latest advancements in chewable dosage forms for human and veterinary use, highlighting the motivations behind their use and covering formulation considerations, as well as regulatory aspects. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Prediction of Solid-State Form of SLS 3D Printed Medicines Using NIR and Raman Spectroscopy.
- Author
-
Trenfield, Sarah J., Januskaite, Patricija, Goyanes, Alvaro, Wilsdon, David, Rowland, Martin, Gaisford, Simon, and Basit, Abdul W.
- Subjects
NEAR infrared spectroscopy ,RAMAN spectroscopy ,DRUG solubility ,SELECTIVE laser sintering ,NEAR infrared radiation ,THREE-dimensional printing ,MOLECULAR weights ,NEAR infrared reflectance spectroscopy - Abstract
Selective laser sintering (SLS) 3D printing is capable of revolutionising pharmaceutical manufacturing, by producing amorphous solid dispersions in a one-step manufacturing process. Here, 3D-printed formulations loaded with a model BCS class II drug (20% w/w itraconazole) and three grades of hydroxypropyl cellulose (HPC) polymer (-SSL, -SL and -L) were produced using SLS 3D printing. Interestingly, the polymers with higher molecular weights (HPC-L and -SL) were found to undergo a uniform sintering process, attributed to the better powder flow characteristics, compared with the lower molecular weight grade (HPC-SSL). XRPD analyses found that the SLS 3D printing process resulted in amorphous conversion of itraconazole for all three polymers, with HPC-SSL retaining a small amount of crystallinity on the drug product surface. The use of process analytical technologies (PAT), including near infrared (NIR) and Raman spectroscopy, was evaluated, to predict the amorphous content, qualitatively and quantitatively, within itraconazole-loaded formulations. Calibration models were developed using partial least squares (PLS) regression, which successfully predicted amorphous content across the range of 0–20% w/w. The models demonstrated excellent linearity (R
2 = 0.998 and 0.998) and accuracy (RMSEP = 1.04% and 0.63%) for NIR and Raman spectroscopy models, respectively. Overall, this article demonstrates the feasibility of SLS 3D printing to produce solid dispersions containing a BCS II drug, and the potential for NIR and Raman spectroscopy to quantify amorphous content as a non-destructive quality control measure at the point-of-care. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
4. A Proof of Concept for 3D Printing of Solid Lipid-Based Formulations of Poorly Water-Soluble Drugs to Control Formulation Dispersion Kinetics.
- Author
-
Vithani, Kapilkumar, Goyanes, Alvaro, Jannin, Vincent, Basit, Abdul W., Gaisford, Simon, and Boyd, Ben J.
- Subjects
- *
THREE-dimensional printing , *DOSAGE forms of drugs , *DRUG control , *DISPERSION (Chemistry) , *PROOF of concept - Abstract
Purpose: The use of three-dimensional printing (3DP) in the development of pharmaceutical dosage forms is growing rapidly. However, the research is almost exclusively focussed on polymer-based systems with very little reported on 3D printing of lipid-based formulations. Thus, the aim of the work was to explore the feasibility of 3DP technology to prepare solid lipid-based formulations. Here, 3DP was applied for the preparation of solid self-microemulsifying drug delivery systems (S-SMEDDS) with defined surface area to volume (SA/V) ratios. Methods: The S-SMEDDS formulations, comprised of Gelucire® 44/14, Gelucire® 48/16 and Kolliphor® P 188 were loaded with fenofibrate or cinnarizine as model drugs. The formulations were printed into four geometrical shapes - cylindrical, prism, cube and torus, and compared to a control cube manually prepared from bulk formulation. Results: The printing process was not significantly affected by the presence of the model drugs. The as-printed S-SMEDDS formulations were characterised using differential scanning calorimetry and wide-angle X-ray scattering. The kinetics of dispersion depended on the SA/V ratio values. The digestion process was affected by the initial geometry of the dosage form by virtue of the kinetics of dispersion of the dosage forms into the digestion medium. Conclusions: This proof of concept study has demonstrated the potential of 3DP for the development of customised S-SMEDDS formulations without the need for an additional carrier or additive and with optimisation could elaborate a new class of dosage forms based on 3D printed lipids. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. 3D printed drug products: Non-destructive dose verification using a rapid point-and-shoot approach.
- Author
-
Trenfield, Sarah J, Goyanes, Alvaro, Telford, Richard, Wilsdon, David, Rowland, Martin, Gaisford, Simon, and Basit, Abdul W
- Subjects
- *
DRUG delivery systems , *DRUG development , *THREE-dimensional printing , *NEAR infrared spectroscopy , *DISPERSION (Chemistry) - Abstract
Graphical abstract Abstract Three-dimensional printing (3DP) has the potential to cause a paradigm shift in the manufacture of pharmaceuticals, enabling personalised medicines to be produced on-demand. To facilitate integration into healthcare, non-destructive characterisation techniques are required to ensure final product quality. Here, the use of process analytical technologies (PAT), including near infrared spectroscopy (NIR) and Raman confocal microscopy, were evaluated on paracetamol-loaded 3D printed cylindrical tablets composed of an acrylic polymer (Eudragit L100-55). Using a portable NIR spectrometer, a calibration model was developed, which predicted successfully drug concentration across the range of 4–40% w/w. The model demonstrated excellent linearity (R2 = 0.996) and accuracy (RMSEP = 0.63%) and results were confirmed with conventional HPLC analysis. The model maintained high accuracy for tablets of a different geometry (torus shapes), a different formulation type (oral films) and when the polymer was changed from acrylic to cellulosic (hypromellose, HPMC). Raman confocal microscopy showed a homogenous drug distribution, with paracetamol predominantly present in the amorphous form as a solid dispersion. Overall, this article is the first to report the use of a rapid ‘point-and-shoot’ approach as a non-destructive quality control method, supporting the integration of 3DP for medicine production into clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. 3D printing of drug-loaded gyroid lattices using selective laser sintering.
- Author
-
Fina, Fabrizio, Goyanes, Alvaro, Madla, Christine M., Awad, Atheer, Trenfield, Sarah J., Kuek, Jia Min, Patel, Pavanesh, Gaisford, Simon, and Basit, Abdul W.
- Subjects
- *
THREE-dimensional printing , *PHARMACEUTICAL industry , *SELECTIVE laser sintering , *CRYSTAL lattices , *ACETAMINOPHEN , *POLYETHYLENE oxide - Abstract
Three-dimensional printing (3DP) is gaining momentum in the field of pharmaceuticals, offering innovative opportunities for medicine manufacture. Selective laser sintering (SLS) is a novel, high resolution and single-step printing technology that we have recently introduced to the pharmaceutical sciences. The aim of this work was to use SLS 3DP to fabricate printlets (3D printed tablets) with cylindrical, gyroid lattice and bi-layer structures having customisable release characteristics. Paracetamol-loaded constructs from four different pharmaceutical grade polymers including polyethylene oxide, Eudragit (L100-55 and RL) and ethyl cellulose, were created using SLS 3DP. The novel gyroid lattice structure was able to modulate the drug release from all four polymers. This work is the first to demonstrate the feasibility of using SLS to achieve customised drug release properties of several polymers, in a swift, cost-effective manner, avoiding the need to alter the formulation composition. By creating these constructs, it is therefore possible to modify drug release, which in practice, could enable the tailoring of drug performance to the patient simply by changing the 3D design. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Fabrication of drug-loaded hydrogels with stereolithographic 3D printing.
- Author
-
Martinez, Pamela Robles, Goyanes, Alvaro, Basit, Abdul W., and Gaisford, Simon
- Subjects
- *
THREE-dimensional printing , *DRUG development , *HYDROGELS , *STEREOLITHOGRAPHY , *FABRICATION (Manufacturing) , *IBUPROFEN - Abstract
3D printing (3DP) technologies have been attracting much recent interest as new methods of fabricating medicines and medical devices. Of the many types of 3DP available, stereolithographic (SLA) printing offers the unique advantage of being able to fabricate objects by cross-linking resins to form networked polymer matrices. Because water can be entrapped in these matrices, it is possible in principle to fabricate pre-wetted, drug-loaded hydrogels and devices. Here, SLA printing was used to prepare ibuprofen-loaded hydrogels of cross-linked polyethylene glycol diacrylate. Hydrogels containing up to 30% w/w water, and 10% w/w ibuprofen, were successfully printed. Dissolution profiles showed that drug release rates were dependent on water content, with higher water content hydrogels releasing drug faster. The conclusion is that SLA 3DP offers a new manufacturing route to pharmaceutical hydrogels. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Selective laser sintering (SLS) 3D printing of medicines.
- Author
-
Fina, Fabrizio, Goyanes, Alvaro, Gaisford, Simon, and Basit, Abdul W.
- Subjects
- *
SELECTIVE laser sintering , *THREE-dimensional printing , *CERAMIC material manufacturing , *ORAL medication , *RAPID prototyping , *INDIVIDUALIZED medicine - Abstract
Selective laser sintering (SLS) 3-dimensional printing is currently used for industrial manufacturing of plastic, metallic and ceramic objects. To date there have been no reports on the use of SLS to fabricate oral drug loaded products; therefore, the aim of this work was to explore the suitability of SLS printing for manufacturing medicines. Two thermoplastic pharmaceutical grade polymers, Kollicoat IR (75% polyvinyl alcohol and 25% polyethylene glycol copolymer) and Eudragit L100-55 (50% methacrylic acid and 50% ethyl acrylate copolymer), with immediate and modified release characteristics respectively, were selected to investigate the versatility of a SLS printer. Each polymer was investigated with three different drug loadings of paracetamol (acetaminophen) (5, 20 and 35%). To aid the sintering process, 3% Candurin ® gold sheen was added to each of the powdered formulations. In total, six solid formulations were successfully printed; the printlets (3D printed tablets) were robust, and no evidence of drug degradation was observed. In biorelevant bicarbonate dissolution media, the Kollicoat formulations showed pH-independent release characteristics, with the release rate dependent on the drug content. In the case of the Eudragit formulations, these showed pH-dependent, modified-release profiles independent of drug loading, with complete release being achieved over 12 h. In conclusion, this work has demonstrated that SLS is a versatile and practical 3D printing technology which can be applied to the pharmaceutical field, thus widening the armamentarium of 3D printing technologies available for the manufacture of modern medicines. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Patient-specific 3D scanned and 3D printed antimicrobial polycaprolactone wound dressings.
- Author
-
Muwaffak, Zaid, Goyanes, Alvaro, Clark, Vivienne, Basit, Abdul W., Hilton, Stephen T., and Gaisford, Simon
- Subjects
- *
THREE-dimensional printing , *POLYCAPROLACTONE , *TRAUMA surgery , *DRUG approval , *ATOMIC emission spectroscopy ,SIDE effects of anti-infective agents - Abstract
The increasing prevalence of wound infections caused by antibiotic resistant bacteria is an urgent challenge facing modern medicine. To address this issue the expedient use of antimicrobial metals such as zinc, copper and silver were incorporated into an FDA-approved polymer (polycaprolactone – PCL) to produce filaments for 3D printing. These metals have broad-spectrum antimicrobial properties, and moreover, copper and zinc can enhance the wound healing process. 3D scanning was used to construct 3D models of a nose and ear to provide the opportunity to customize shape and size of a wound dressing to an individual patient. Hot melt extrusion was used to extrude pellets obtained by vacuum-drying of solutions of PCL and the different metals in order to manufacture metal-homogeneously-loaded filaments. Wound dressings with different shapes were produced with the filaments containing different concentrations of metals. Release of the metals from the dressings was determined by inductively coupled plasma atomic emission spectroscopy. All the different metal dressings show fast release (up to 24 h) followed by slow release (up to 72 h). The antibacterial efficacy of the wound dressings was tested using a thermal activity monitor system, revealing that silver and copper wound dressings had the most potent bactericidal properties. This study shows that 3D scanning and 3D printing, which are becoming simpler and more affordable, have the potential to offer solutions to produce personalised wound dressings. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Development of modified release 3D printed tablets (printlets) with pharmaceutical excipients using additive manufacturing.
- Author
-
Goyanes, Alvaro, Fina, Fabrizio, Martorana, Annalisa, Sedough, Daniel, Gaisford, Simon, and Basit, Abdul W.
- Subjects
- *
DRUG tablets , *THREE-dimensional printing , *COMPUTED tomography , *FUSED deposition modeling , *EXCIPIENTS - Abstract
The aim of this study was to manufacture 3D printed tablets (printlets) from enteric polymers by single filament fused deposition modeling (FDM) 3D printing (3DP). Hot melt extrusion was used to generate paracetamol-loaded filaments from three different grades of the pharmaceutical excipient hypromellose acetate succinate (HPMCAS), grades LG, MG and HG. One-step 3DP was used to process these filaments into enteric printlets incorporating up to 50% drug loading with two different infill percentages (20 and 100%). X-ray Micro Computed Tomography (Micro-CT) analysis revealed that printlets with 20% infill had cavities in the core compared to 100% infill, and that the density of the 50% drug loading printlets was higher than the equivalent formulations loaded with 5% drug. In biorelevant bicarbonate dissolution media, drug release from the printlets was dependent on the polymer composition, drug loading and the internal structure of the formulations. All HPMCAS-based printlets showed delayed drug release properties, and in the intestinal conditions, drug release was faster from the printlets prepared with polymers with a lower pH-threshold: HPMCAS LG > HPMCAS MG > HPMCAS HG. These results confirm that FDM 3D printing makes it possible not only to manufacture delayed release printlets without the need for an outer enteric coating, but it is also feasible to adapt the release profile in response to the personal characteristics of the patient, realizing the full potential of additive manufacturing in the development of personalised dose medicines. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
11. 3D scanning and 3D printing as innovative technologies for fabricating personalized topical drug delivery systems.
- Author
-
Goyanes, Alvaro, Det-Amornrat, Usanee, Wang, Jie, Basit, Abdul W., and Gaisford, Simon
- Subjects
- *
ACNE , *SKIN disease treatment , *DRUG delivery systems , *SALICYLIC acid , *THREE-dimensional printing , *FUSED deposition modeling - Abstract
Acne is a multifactorial inflammatory skin disease with high prevalence. In this work, the potential of 3D printing to produce flexible personalised-shape anti -acne drug (salicylic acid) loaded devices was demonstrated by two different 3D printing (3DP) technologies: Fused Deposition Modelling (FDM) and stereolithography (SLA). 3D scanning technology was used to obtain a 3D model of a nose adapted to the morphology of an individual. In FDM 3DP, commercially produced Flex EcoPLA™ (FPLA) and polycaprolactone (PCL) filaments were loaded with salicylic acid by hot melt extrusion (HME) (theoretical drug loading — 2% w/w) and used as feedstock material for 3D printing. Drug loading in the FPLA-salicylic acid and PCL-salicylic acid 3D printed patches was 0.4% w/w and 1.2% w/w respectively, indicating significant thermal degradation of drug during HME and 3D printing. Diffusion testing in Franz cells using a synthetic membrane revealed that the drug loaded printed samples released < 187 μg/cm 2 within 3 h. FPLA-salicylic acid filament was successfully printed as a nose-shape mask by FDM 3DP, but the PCL-salicylic acid filament was not. In the SLA printing process, the drug was dissolved in different mixtures of poly(ethylene glycol) diacrylate (PEGDA) and poly(ethylene glycol) (PEG) that were solidified by the action of a laser beam. SLA printing led to 3D printed devices (nose-shape) with higher resolution and higher drug loading (1.9% w/w) than FDM, with no drug degradation. The results of drug diffusion tests revealed that drug diffusion was faster than with the FDM devices, 229 and 291 μg/cm 2 within 3 h for the two formulations evaluated. In this study, SLA printing was the more appropriate 3D printing technology to manufacture anti -acne devices with salicylic acid. The combination of 3D scanning and 3D printing has the potential to offer solutions to produce personalised drug loaded devices, adapted in shape and size to individual patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
12. Fabrication of controlled-release budesonide tablets via desktop (FDM) 3D printing.
- Author
-
Goyanes, Alvaro, Chang, Hanah, Sedough, Daniel, Hatton, Grace B., Wang, Jie, Buanz, Asma, Gaisford, Simon, and Basit, Abdul W.
- Subjects
- *
CONTROLLED release drugs , *BUDESONIDE , *DRUG tablets , *THREE-dimensional printing , *FUSED deposition modeling , *DOSAGE forms of drugs - Abstract
The aim of this work was to explore the feasibility of using fused deposition modelling (FDM) 3D printing (3DP) technology with hot melt extrusion (HME) and fluid bed coating to fabricate modified-release budesonide dosage forms. Budesonide was sucessfully loaded into polyvinyl alcohol filaments using HME. The filaments were engineered into capsule-shaped tablets (caplets) containing 9 mg budesonide using a FDM 3D printer; the caplets were then overcoated with a layer of enteric polymer. The final printed formulation was tested in a dynamic dissolution bicarbonate buffer system, and two commercial budesonide products, Cortiment ® (Uceris ® ) and Entocort ® , were also investigated for comparison. Budesonide release from the Entocort ® formulation was rapid in conditions of the upper small intestine while release from the Cortiment ® product was more delayed and very slow. In contrast, the new 3D printed caplet formulation started to release in the mid-small intestine but release then continued in a sustained manner throughout the distal intestine and colon. This work has demonstrated the potential of combining FDM 3DP with established pharmaceutical processes, including HME and film coating, to fabricate modified release oral dosage forms. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. Effect of geometry on drug release from 3D printed tablets.
- Author
-
Goyanes, Alvaro, Robles Martinez, Pamela, Buanz, Asma, Basit, Abdul W., and Gaisford, Simon
- Subjects
- *
CONTROLLED release drugs , *THREE-dimensional printing , *DRUG tablets , *EXTRUSION process , *DRUG stability , *COMPACTING , *POLYVINYL alcohol - Abstract
The aim of this work was to explore the feasibility of combining hot melt extrusion (HME) with 3D printing (3DP) technology, with a view to producing different shaped tablets which would be otherwise difficult to produce using traditional methods. A filament extruder was used to obtain approx. 4% paracetamol loaded filaments of polyvinyl alcohol with characteristics suitable for use in fused-deposition modelling 3DP. Five different tablet geometries were successfully 3D-printed—cube, pyramid, cylinder, sphere and torus. The printing process did not affect the stability of the drug. Drug release from the tablets was not dependent on the surface area but instead on surface area to volume ratio, indicating the influence that geometrical shape has on drug release. An erosion-mediated process controlled drug release. This work has demonstrated the potential of 3DP to manufacture tablet shapes of different geometries, many of which would be challenging to manufacture by powder compaction. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. Fused-filament 3D printing (3DP) for fabrication of tablets.
- Author
-
Goyanes, Alvaro, Buanz, Asma B.M., Basit, Abdul W., and Gaisford, Simon
- Subjects
- *
DRUG tablets , *FABRICATION (Manufacturing) , *DRUG dosage , *POLYVINYL alcohol , *DISSOLUTION (Chemistry) , *THREE-dimensional printing , *CONTROLLED release drugs - Abstract
The use of fused-filament 3D printing (FF 3DP) to fabricate individual tablets is demonstrated. The technology permits the manufacture of tablets containing drug doses tailored to individual patients, or to fabrication of tablets with specific drug-release profiles. Commercially produced polyvinyl alcohol (PVA) filament was loaded with a model drug (fluorescein) by swelling of the polymer in ethanolic drug solution. A final drug-loading of 0.29% w/w was achieved. Tablets of PVA/fluorescein (10 mm diameter) were printed using a 3D printer. It was found that changing the degree of infill percentage in the printer software varied the weight and volume of the printed tablets. The tablets were mechanically strong and no significant thermal degradation of the active occurred during printing. Dissolution tests were conducted in modified Hank’s buffer. The results showed release profiles were dependent on the infill percentage used to print the tablet. The study indicates that FF 3DP has the potential to offer a new solution for fabricating personalized-dose medicines or unit dosage forms with controlled-release profiles. In addition, the low cost of FDM printers means the paradigm of extemporaneous or point-of-use manufacture of personalized-dose tablets is both feasible and attainable. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
15. 3D Printed Punctal Plugs for Controlled Ocular Drug Delivery.
- Author
-
Xu, Xiaoyan, Awwad, Sahar, Diaz-Gomez, Luis, Alvarez-Lorenzo, Carmen, Brocchini, Steve, Gaisford, Simon, Goyanes, Alvaro, and Basit, Abdul W.
- Subjects
CONTROLLED drugs ,DRY eye syndromes ,POLYETHYLENE glycol ,EYE drops ,THREE-dimensional printing ,OPHTHALMIC drugs ,DEXAMETHASONE - Abstract
Dry eye disease is a common ocular disorder that is characterised by tear deficiency or excessive tear evaporation. Current treatment involves the use of eye drops; however, therapeutic efficacy is limited because of poor ocular bioavailability of topically applied formulations. In this study, digital light processing (DLP) 3D printing was employed to develop dexamethasone-loaded punctal plugs. Punctal plugs with different drug loadings were fabricated using polyethylene glycol diacrylate (PEGDA) and polyethylene glycol 400 (PEG 400) to create a semi-interpenetrating network (semi-IPN). Drug-loaded punctal plugs were characterised in terms of physical characteristics (XRD and DSC), potential drug-photopolymer interactions (FTIR), drug release profile, and cytocompatibility. In vitro release kinetics of the punctal plugs were evaluated using an in-house flow rig model that mimics the subconjunctival space. The results showed sustained release of dexamethasone for up to 7 days from punctal plugs made with 20% w/w PEG 400 and 80% w/w PEGDA, while punctal plugs made with 100% PEGDA exhibited prolonged releases for more than 21 days. Herein, our study demonstrates that DLP 3D printing represents a potential manufacturing platform for fabricating personalised drug-loaded punctal plugs with extended release characteristics for ocular administration. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Direct Powder Extrusion 3D Printing of Praziquantel to Overcome Neglected Disease Formulation Challenges in Paediatric Populations.
- Author
-
Boniatti, Janine, Januskaite, Patricija, Fonseca, Laís B. da, Viçosa, Alessandra L., Amendoeira, Fábio C., Tuleu, Catherine, Basit, Abdul W., Goyanes, Alvaro, and Ré, Maria-Inês
- Subjects
NEGLECTED diseases ,THREE-dimensional printing ,FUSED deposition modeling ,PRAZIQUANTEL ,DRUG solubility ,ITRACONAZOLE ,AMORPHOUS substances - Abstract
For the last 40 years, praziquantel has been the standard treatment for schistosomiasis, a neglected parasitic disease affecting more than 250 million people worldwide. However, there is no suitable paediatric formulation on the market, leading to off-label use and the splitting of commercial tablets for adults. In this study, we use a recently available technology, direct powder extrusion (DPE) three-dimensional printing (3DP), to prepare paediatric Printlets™ (3D printed tablets) of amorphous solid dispersions of praziquantel with Kollidon
® VA 64 and surfactants (Span™ 20 or Kolliphor® SLS). Printlets were successfully printed from both pellets and powders obtained from extrudates by hot melt extrusion (HME). In vitro dissolution studies showed a greater than four-fold increase in praziquantel release, due to the formation of amorphous solid dispersions. In vitro palatability data indicated that the printlets were in the range of praziquantel tolerability, highlighting the taste masking capabilities of this technology without the need for additional taste masking excipients. This work has demonstrated the possibility of 3D printing tablets using pellets or powder forms obtained by HME, avoiding the use of filaments in fused deposition modelling 3DP. Moreover, the main formulation hurdles of praziquantel, such as low drug solubility, inadequate taste, and high and variable dose requirements, can be overcome using this technology. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
17. Stereolithography (SLA) 3D printing of a bladder device for intravesical drug delivery.
- Author
-
Xu, Xiaoyan, Goyanes, Alvaro, Trenfield, Sarah J., Diaz-Gomez, Luis, Alvarez-Lorenzo, Carmen, Gaisford, Simon, and Basit, Abdul W.
- Subjects
- *
DRUG delivery devices , *THREE-dimensional printing , *STEREOLITHOGRAPHY , *BLADDER , *ORAL medication , *COMPRESSIVE force - Abstract
Intravesical instillation therapy is an alternative approach to oral medications for the treatment of severe bladder diseases, offering high drug concentrations at the site of action while minimising systemic side effects. However, therapeutic efficacy is often limited because of the short residence time of the drug in the bladder and the need for repeated instillations. This study reports, for the first time, the use of stereolithography (SLA) 3D printing to manufacture novel indwelling bladder devices using an elastic polymer to achieve extended and localised delivery of lidocaine hydrochloride. The devices were designed to be inserted into and retrieved from the bladder using a urethral catheter. Two types of bladder devices (hollow and solid) were prepared with a resilient material (Elastic Resin) incorporating three drug loads of lidocaine hydrochloride (10% w/w, 30% w/w and 50% w/w); a drug frequently used to treat interstitial cystitis and bladder pain. All of the devices showed acceptable blood compatibility, good resistance to compressive and stretching forces and were able to recover their original shape immediately once external forces were removed. In vitro drug release studies showed that a complete release of lidocaine was achieved within 4 days from the hollow devices, whereas the solid devices enabled sustained drug release for up to 14 days. SLA 3D printing therefore provides a new manufacturing route to produce bladder-retentive drug delivery devices using elastic polymers, and offers a revolutionary and personalised approach for clinical intravesical drug delivery. Unlabelled Image • Stereolithography (SLA) 3D printing was used to fabricate novel indwelling bladder devices for intravesical drug delivery. • Two types of devices (hollow and solid) were prepared with Elastic Resin incorporating different loadings of lidocaine. • The fabricated devices showed acceptable blood compatibility, good resistance to compressive and stretching forces. • Sustained release of lidocaine was achieved within 4 days from the hollow devices and up to 14 days from the solid devices. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. 3D Printed Tacrolimus Rectal Formulations Ameliorate Colitis in an Experimental Animal Model of Inflammatory Bowel Disease.
- Author
-
Seoane-Viaño, Iria, Gómez-Lado, Noemí, Lázare-Iglesias, Héctor, García-Otero, Xurxo, Antúnez-López, José Ramón, Ruibal, Álvaro, Varela-Correa, Juan Jesús, Aguiar, Pablo, Basit, Abdul W., Otero-Espinar, Francisco J., González-Barcia, Miguel, Goyanes, Alvaro, Luzardo-Álvarez, Asteria, and Fernández-Ferreiro, Anxo
- Subjects
INFLAMMATORY bowel diseases ,COLITIS ,LABORATORY animals ,TACROLIMUS ,ANIMAL models in research - Abstract
The aim of this study was to fabricate novel self-supporting tacrolimus suppositories using semisolid extrusion 3-dimensional printing (3DP) and to investigate their efficacy in an experimental model of inflammatory bowel disease. Blends of Gelucire 44/14 and coconut oil were employed as lipid excipients to obtain suppository formulations with self-emulsifying properties, which were then tested in a TNBS (2,4,6-trinitrobenzenesulfonic acid) induced rat colitis model. Disease activity was monitored using PET/CT medical imaging; maximum standardized uptake values (SUV
max ), a measure of tissue radiotracer accumulation rate, together with body weight changes and histological assessments, were used as inflammatory indices to monitor treatment efficacy. Following tacrolimus treatment, a significant reduction in SUVmax was observed on days 7 and 10 in the rat colon sections compared to non-treated animals. Histological analysis using Nancy index confirmed disease remission. Moreover, statistical analysis showed a positive correlation (R2 = 71.48%) between SUVmax values and weight changes over time. Overall, this study demonstrates the effectiveness of 3D printed tacrolimus suppositories to ameliorate colitis and highlights the utility of non-invasive PET/CT imaging to evaluate new therapies in the preclinical area. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
19. I Spy with My Little Eye: A Paediatric Visual Preferences Survey of 3D Printed Tablets.
- Author
-
Januskaite, Patricija, Xu, Xiaoyan, Ranmal, Sejal R., Gaisford, Simon, Basit, Abdul W., Tuleu, Catherine, and Goyanes, Alvaro
- Subjects
FUSED deposition modeling ,SELECTIVE laser sintering ,THREE-dimensional printing ,PATIENT compliance ,INSPECTION & review ,DEGLUTITION ,SENSORY perception - Abstract
3D printing (3DP) in the pharmaceutical field is a disruptive technology that allows the preparation of personalised medicines at the point of dispensing. The paediatric population presents a variety of pharmaceutical formulation challenges such as dose flexibility, patient compliance, taste masking and the fear or difficulty to swallow tablets, all factors that could be overcome using the adaptable nature of 3DP. User acceptability studies of 3D printed formulations have been previously carried out in adults; however, feedback from children themselves is essential in establishing the quality target product profile towards the development of age-appropriate medicines. The aim of this study was to investigate the preference of children for different 3D printed tablets (Printlets™) as an important precursor to patient acceptability studies. Four different 3DP technologies; digital light processing (DLP), selective laser sintering (SLS), semi-solid extrusion (SSE) and fused deposition modeling (FDM) were used to prepare placebo printlets with similar physical attributes including size and shape. A single-site, two-part survey was completed with participants aged 4–11 years to determine their preference and opinions based on visual inspection of the printlets. A total of 368 participants completed an individual open questionnaire to visually select the best and worst printlet, and 310 participants completed further non-compulsory open questions to elaborate on their choices. Overall, the DLP printlets were the most visually appealing to the children (61.7%) followed by the SLS printlets (21.2%), and with both the FDM (5.4%) and SSE (11.7%) printlets receiving the lowest scores. However, after being informed that the SSE printlets were chewable, the majority of participants changed their selection and favoured this printlet, despite their original choice, in line with children's preference towards chewable dosage forms. Participant age and sex displayed no significant differences in printlet selection. Printlet descriptions were grouped into four distinct categories; appearance, perceived taste, texture and familiarity, and were found to be equally important when creating a quality target product profile for paediatric 3D printed formulations. This study is the first to investigate children's perceptions of printlets, and the findings aim to provide guidance for further development of paediatric-appropriate medicines using different 3DP technologies. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. 3D Printing of Tunable Zero-Order Release Printlets.
- Author
-
Fina, Fabrizio, Goyanes, Alvaro, Rowland, Martin, Gaisford, Simon, and W. Basit, Abdul
- Subjects
- *
THREE-dimensional printing , *PHARMACOLOGY , *DRUG side effects , *COMPUTER-aided design , *DRUG design - Abstract
Zero-order release formulations are designed to release a drug at a constant rate over a prolonged time, thus reducing systemic side effects and improving patience adherence to the therapy. Such formulations are traditionally complex to manufacture, requiring multiple steps. In this work, fused deposition modeling (FDM) 3D printing was explored to prepare on-demand printlets (3D printed tablets). The design includes a prolonged release core surrounded by an insoluble shell able to provide zero-order release profiles. The effect of drug loading (10, 25, and 40% w/w paracetamol) on the mechanical and physical properties of the hot melt extruded filaments and 3D printed formulations was evaluated. Two different shell 3D designs (6 mm and 8 mm diameter apertures) together with three different core infills (100, 50, and 25%) were prepared. The formulations showed a range of zero-order release profiles spanning 16 to 48 h. The work has shown that with simple formulation design modifications, it is possible to print extended release formulations with tunable, zero-order release kinetics. Moreover, by using different infill percentages, the dose contained in the printlet can be infinitely adjusted, providing an additive manufacturing route for personalizing medicines to a patient. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. 3D Printed Tablets (Printlets) with Braille and Moon Patterns for Visually Impaired Patients.
- Author
-
Awad, Atheer, Yao, Aliya, Trenfield, Sarah J., Goyanes, Alvaro, Gaisford, Simon, and Basit, Abdul W.
- Subjects
PATIENT compliance ,VISION disorders ,BRAILLE ,MEDICATION errors ,HEALTH care reminder systems ,BLIND people ,BLINDNESS - Abstract
Visual impairment and blindness affects 285 million people worldwide, resulting in a high public health burden. This study reports, for the first time, the use of three-dimensional (3D) printing to create orally disintegrating printlets (ODPs) suited for patients with visual impairment. Printlets were designed with Braille and Moon patterns on their surface, enabling patients to identify medications when taken out of their original packaging. Printlets with different shapes were fabricated to offer additional information, such as the medication indication or its dosing regimen. Despite the presence of the patterns, the printlets retained their original mechanical properties and dissolution characteristics, wherein all the printlets disintegrated within ~5 s, avoiding the need for water and facilitating self-administration of medications. Moreover, the readability of the printlets was verified by a blind person. Overall, this novel and practical approach should reduce medication errors and improve medication adherence in patients with visual impairment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. Selective Laser Sintering 3D Printing of Orally Disintegrating Printlets Containing Ondansetron.
- Author
-
Allahham, Nour, Fina, Fabrizio, Marcuta, Carmen, Kraschew, Lilia, Mohr, Wolfgang, Gaisford, Simon, Basit, Abdul W., and Goyanes, Alvaro
- Subjects
SELECTIVE laser sintering ,THREE-dimensional printing ,RAPID prototyping ,COMMERCIAL products ,MANNITOL - Abstract
The aim of this work was to explore the feasibility of using selective laser sintering (SLS) 3D printing (3DP) to fabricate orodispersable printlets (ODPs) containing ondansetron. Ondansetron was first incorporated into drug-cyclodextrin complexes and then combined with the filler mannitol. Two 3D printed formulations with different levels of mannitol were prepared and tested, and a commercial ondansetron orally disintegrating tablet (ODT) product (Vonau
® Flash) was also investigated for comparison. Both 3D printed formulations disintegrated at ~15 s and released more than 90% of the drug within 5 min independent of the mannitol content; these results were comparable to those obtained with the commercial product. This work demonstrates the potential of SLS 3DP to fabricate orodispersible printlets with characteristics similar to a commercial ODT, but with the added benefit of using a manufacturing technology able to prepare medicines individualized to the patient. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
23. Advances in powder bed fusion 3D printing in drug delivery and healthcare.
- Author
-
Awad, Atheer, Fina, Fabrizio, Goyanes, Alvaro, Gaisford, Simon, and Basit, Abdul W.
- Subjects
- *
THREE-dimensional printing , *DIRECT metal laser sintering , *ELECTRON beam furnaces , *SELECTIVE laser sintering , *POWDERS - Abstract
[Display omitted] Powder bed fusion (PBF) is a 3D printing method that selectively consolidates powders into 3D objects using a power source. PBF has various derivatives; selective laser sintering/melting, direct metal laser sintering, electron beam melting and multi-jet fusion. These technologies provide a multitude of benefits that make them well suited for the fabrication of bespoke drug-laden formulations, devices and implants. This includes their superior printing resolution and speed, and ability to produce objects without the need for secondary supports, enabling them to precisely create complex products. Herein, this review article outlines the unique applications of PBF 3D printing, including the main principles underpinning its technologies and highlighting their novel pharmaceutical and biomedical applications. The challenges and shortcomings are also considered, emphasising on their effects on the 3D printed products, whilst providing a forward-thinking view. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Automated therapy preparation of isoleucine formulations using 3D printing for the treatment of MSUD: First single-centre, prospective, crossover study in patients.
- Author
-
Goyanes, Alvaro, Madla, Christine M., Umerji, Aysha, Duran Piñeiro, Goretti, Giraldez Montero, Jose Maria, Lamas Diaz, María Jesús, Gonzalez Barcia, Miguel, Taherali, Farhan, Sánchez-Pintos, Paula, Couce, Maria-Luz, Gaisford, Simon, and Basit, Abdul W.
- Subjects
- *
THREE-dimensional printing , *THERAPEUTICS , *LEUCINE , *URINALYSIS , *ISOLEUCINE , *MAPLE syrup urine disease - Abstract
Maple syrup urine disease (MSUD) is a rare metabolic disorder with a worldwide prevalence of 1 in every 185,000 live births. However, certain populations display a significant overexpression of the disorder where incidence is reported to be 1 in every 52,541 new-borns. The first-line therapy for MSUD involves a strict dietary leucine restriction and oral supplementation of isoleucine and valine. The dose administered to patients requires strict tailoring according to age, weight and blood levels. In current clinical practice, however, practitioners still have to prepare extemporaneous formulations due to the lack of suitable oral treatments for MSUD. Herein, we evaluate the first time use of 3D printing in a hospital setting for the preparation of personalised therapies with the aim of improving safety and acceptability to isoleucine supplementation in paediatric patients suffering from MSUD. This investigation was a single-centre, prospective crossover experimental study. Four paediatric patients with MSUD (aged 3–16 years) were treated at the Clinic University Hospital in Santiago de Compostela, Spain which is a MSUD reference hospital in Europe. The primary objective was to evaluate isoleucine blood levels after six months of treatment with two types of formulations; conventional capsules prepared by manual compounding and personalised chewable formulations prepared by automated 3D printing. A secondary investigation was to evaluate patient acceptability of 3D printed formulations prepared with different flavours and colours. Isoleucine blood levels in patients were well controlled using both types of formulations, however, the 3D printed therapy showed mean levels closer to the target value and with less variability (200–400 µM). The 3D printed formulations were well accepted by patients regarding flavour and colour. The study demonstrates for the first time that 3D printing offers a feasible, rapid and automated approach to prepare oral tailored-dose therapies in a hospital setting. 3D printing has shown to be an effective manufacturing technology in producing chewable isoleucine printlets as a treatment of MSUD with good acceptability. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Direct powder extrusion 3D printing: Fabrication of drug products using a novel single-step process.
- Author
-
Goyanes, Alvaro, Allahham, Nour, Trenfield, Sarah J., Stoyanov, Edmont, Gaisford, Simon, and Basit, Abdul W.
- Subjects
- *
THREE-dimensional printing , *FUSED deposition modeling , *AMORPHOUS substances , *DRUG solubility , *MELT spinning , *DRUG abuse - Abstract
Three-dimensional (3D) printing is revolutionising how we envision manufacturing in the pharmaceutical field. Here, we report for the first time the use of direct powder extrusion 3D printing: a novel single-step printing process for the production of printlets (3D printed tablets) directly from powdered materials. This new 3D printing technology was used to prepare amorphous solid dispersions of itraconazole using four different grades of hydroxypropylcellulose (HPC – UL, SSL, SL and L). All of the printlets showed good mechanical and physical characteristics and no drug degradation. The printlets showed sustained drug release characteristics, with drug concentrations higher than the solubility of the drug itself. The printlets prepared with the ultra-low molecular grade (HPC – UL) showed faster drug release compared with the other HPC grades, attributed to the fact that itraconazole was found in a higher percentage as an amorphous solid dispersion. This work demonstrates the potential of this innovate technology to overcome one of the major disadvantages of fused deposition modelling (FDM) 3D printing by avoiding the need for preparation of filaments by hot melt extrusion (HME). This novel single-step technology could revolutionise the preparation of amorphous solid dispersions as final formulations and it may be especially suited for preclinical studies, where the quantity of drugs is limited and without the need of using traditional HME. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
26. 3D Printing of a Multi-Layered Polypill Containing Six Drugs Using a Novel Stereolithographic Method.
- Author
-
Robles-Martinez, Pamela, Xu, Xiaoyan, Trenfield, Sarah J., Awad, Atheer, Goyanes, Alvaro, Telford, Richard, Basit, Abdul W., and Gaisford, Simon
- Subjects
THREE-dimensional printing ,DRUG abuse ,RAMAN microscopy ,CAFFEINE ,CHLORAMPHENICOL - Abstract
Three-dimensional printing (3DP) has demonstrated great potential for multi-material fabrication because of its capability for printing bespoke and spatially separated material conformations. Such a concept could revolutionise the pharmaceutical industry, enabling the production of personalised, multi-layered drug products on demand. Here, we developed a novel stereolithographic (SLA) 3D printing method that, for the first time, can be used to fabricate multi-layer constructs (polypills) with variable drug content and/or shape. Using this technique, six drugs, including paracetamol, caffeine, naproxen, chloramphenicol, prednisolone and aspirin, were printed with different geometries and material compositions. Drug distribution was visualised using Raman microscopy, which showed that whilst separate layers were successfully printed, several of the drugs diffused across the layers depending on their amorphous or crystalline phase. The printed constructs demonstrated excellent physical properties and the different material inclusions enabled distinct drug release profiles of the six actives within dissolution tests. For the first time, this paper demonstrates the feasibility of SLA printing as an innovative platform for multi-drug therapy production, facilitating a new era of personalised polypills. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
27. 3D Printed Pellets (Miniprintlets): A Novel, Multi-Drug, Controlled Release Platform Technology.
- Author
-
Awad, Atheer, Fina, Fabrizio, Trenfield, Sarah J., Patel, Pavanesh, Goyanes, Alvaro, Gaisford, Simon, and Basit, Abdul W.
- Subjects
CONTROLLED release drugs ,SELECTIVE laser sintering ,ETHYLCELLULOSE ,THREE-dimensional printing ,DRUG delivery systems ,PHARMACOLOGY - Abstract
Selective laser sintering (SLS) is a single-step three-dimensional printing (3DP) process that can be leveraged to engineer a wide array of drug delivery systems. The aim of this work was to utilise SLS 3DP, for the first time, to produce small oral dosage forms with modified release properties. As such, paracetamol-loaded 3D printed multiparticulates, termed miniprintlets, were fabricated in 1 mm and 2 mm diameters. Despite their large surface area compared with a conventional monolithic tablet, the ethyl cellulose-based miniprintlets exhibited prolonged drug release patterns. The possibility of producing miniprintlets combining two drugs, namely paracetamol and ibuprofen, was also investigated. By varying the polymer, the dual miniprintlets were programmed to achieve customised drug release patterns, whereby one drug was released immediately from a Kollicoat Instant Release matrix, whilst the effect of the second drug was sustained over an extended time span using ethyl cellulose. Herein, this work has highlighted the versatility of SLS 3DP to fabricate small and intricate formulations containing multiple active pharmaceutical ingredients with distinct release properties. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
28. An Overview of 3D Printing Technologies for Soft Materials and Potential Opportunities for Lipid-based Drug Delivery Systems.
- Author
-
Vithani, Kapilkumar, Goyanes, Alvaro, Jannin, Vincent, Basit, Abdul W., Gaisford, Simon, and Boyd, Ben J.
- Subjects
- *
THREE-dimensional printing , *DRUG delivery systems , *PHARMACEUTICAL industry , *STEREOLITHOGRAPHY , *SELECTIVE laser sintering - Abstract
Purpose: Three-dimensional printing (3DP) is a rapidly growing additive manufacturing process and it is predicted that the technology will transform the production of goods across numerous fields. In the pharmaceutical sector, 3DP has been used to develop complex dosage forms of different sizes and structures, dose variations, dose combinations and release characteristics, not possible to produce using traditional manufacturing methods. However, the technology has mainly been focused on polymer-based systems and currently, limited information is available about the potential opportunities for the 3DP of soft materials such as lipids.Methods: This review paper emphasises the most commonly used 3DP technologies for soft materials such as inkjet printing, binder jetting, selective laser sintering (SLS), stereolithography (SLA), fused deposition modeling (FDM) and semi-solid extrusion, with the current status of these technologies for soft materials in biological, food and pharmaceutical applications.Result: The advantages of 3DP, particularly in the pharmaceutical field, are highlighted and an insight is provided about the current studies for lipid-based drug delivery systems evaluating the potential of 3DP to fabricate innovative products. Additionally, the challenges of the 3DP technologies associated with technical processing, regulatory and material issues of lipids are discussed in detail.Conclusion: The future utility of 3DP for printing soft materials, particularly for lipid-based drug delivery systems, offers great advantages and the technology will potentially support patient compliance and drug effectiveness via a personalised medicine approach. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
29. Visualizing disintegration of 3D printed tablets in humans using MRI and comparison with in vitro data.
- Author
-
Seoane-Viaño, Iria, Pérez-Ramos, Tania, Liu, Jiaqi, Januskaite, Patricija, Guerra-Baamonde, Elena, González-Ramírez, Jorge, Vázquez-Caruncho, Manuel, Basit, Abdul W., and Goyanes, Alvaro
- Subjects
- *
SELECTIVE laser sintering , *MAGNETIC resonance imaging , *INDIVIDUALIZED medicine , *THREE-dimensional printing - Abstract
Three-dimensional (3D) printing is revolutionising the way that medicines are manufactured today, paving the way towards more personalised medicine. However, there is limited in vivo data on 3D printed dosage forms, and no studies to date have been performed investigating the intestinal behaviour of these drug products in humans, hindering the complete translation of 3D printed medications into clinical practice. Furthermore, it is unknown whether conventional in vitro release tests can accurately predict the in vivo performance of 3D printed formulations in humans. In this study, selective laser sintering (SLS) 3D printing technology has been used to produce two placebo torus-shaped tablets (printlets) using different laser scanning speeds. The printlets were administered to 6 human volunteers, and in vivo disintegration times were assessed using magnetic resonance imaging (MRI). In vitro disintegration tests were performed using a standard USP disintegration apparatus, as well as an alternative method based on the use of reduced media volume and minimal agitation. Printlets fabricated at a laser scanning speed of 90 mm/s exhibited an average in vitro disintegration time of 7.2 ± 1 min (measured using the USP apparatus) and 25.5 ± 4.1 min (measured using the alternative method). In contrast, printlets manufactured at a higher laser scanning speed of 130 mm/s had an in vitro disintegration time of 2.8 ± 0.8 min (USP apparatus) and 18.8 ± 1.9 min (alternative method). When tested in humans, printlets fabricated at a laser scanning speed of 90 mm/s showed an average disintegration time of 17.3 ± 7.2 min, while those manufactured at a laser scanning speed of 130 mm/s exhibited a shorter disintegration time of 12.7 ± 6.8 min. Although the disintegration times obtained using the alternative method more closely resembled those obtained in vivo, no clear correlation was observed between the in vitro and in vivo disintegration times, highlighting the need to develop better in vitro methodology for 3D printed drug products. [Display omitted] • The disintegration of SLS 3D-printed tablets was evaluated for the first time in human volunteers. • MRI is a useful tool for monitoring 3D printed tablet disintegration in vivo. • Tablets printed with a lower laser scanning speed had longer disintegration times. • No correlation was observed between in vitro and in vivo disintegration times. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Hydroxypropyl-β-cyclodextrin-based fast dissolving carbamazepine printlets prepared by semisolid extrusion 3D printing.
- Author
-
Conceição, Jaime, Farto-Vaamonde, Xián, Goyanes, Alvaro, Adeoye, Oluwatomide, Concheiro, Angel, Cabral-Marques, Helena, Sousa Lobo, José Manuel, and Alvarez-Lorenzo, Carmen
- Subjects
- *
THREE-dimensional printing , *CARBAMAZEPINE , *CELLULOSE - Abstract
• HPβCD was used for the first time to prepare 3D printed formulations (printlets). • Micro-extrusion printing enabled in situ formation of HPβCD-carbamazepine complexes. • Orodispersible and immediate release printlets were successfully prepared. • Small changes in cellulose ethers ratio allowed fine tuning of drug release profile. This work aimed to explore for the first time the use of cyclodextrins to prepare printlets of poorly soluble drugs, such as carbamazepine, which require fine dose adjustment and rapid release. Orodispersible (flash) and immediate release formulations were 3D printed via semisolid extrusion of wet masses of hydroxypropyl-β-cyclodextrin (HPβCD) and cellulose ethers and regulating tablet porosity. Rheology of the wet masses allowed identifying printable compositions. Printing robustness was assessed evaluating weight, dimensions, hardness, drug content, and microstructure. Drug crystallinity, printlet disintegration and dissolution profiles were also characterized. The results highlight the feasibility of using HPβCD as excipient in printlets of poorly soluble drugs, and the possibilities of tuning drug release profiles through small changes in cellulose ethers nature and ratio. Semisolid extrusion-based 3D printing is revealed as a feasible approach to in situ form carbamazepine-HPβCD complexes and to produce printlets with suitable physical and drug release properties for oral delivery. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
31. Reshaping drug development using 3D printing.
- Author
-
Awad, Atheer, Trenfield, Sarah J., Goyanes, Alvaro, Gaisford, Simon, and Basit, Abdul W.
- Subjects
- *
DRUG development , *THREE-dimensional printing , *PHARMACEUTICAL industry , *FABRICATION (Manufacturing) , *LOGISTICS - Abstract
The pharmaceutical industry stands on the brink of a revolution, calling for the recognition and embracement of novel techniques. 3D printing (3DP) is forecast to reshape the way in which drugs are designed, manufactured, and used. Although a clear trend towards personalised fabrication is perceived, here we accentuate the merits and shortcomings of each technology, providing insights into aspects such as the efficiency of production, global supply, and logistics. Contemporary opportunities for 3DP in drug discovery and pharmaceutical development and manufacturing are unveiled, offering a forward-looking view on its potential uses as a digitised tool for personalised dispensing of drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
32. 3D Printing Pharmaceuticals: Drug Development to Frontline Care.
- Author
-
Trenfield, Sarah J., Awad, Atheer, Goyanes, Alvaro, Gaisford, Simon, and Basit, Abdul W.
- Subjects
- *
CONTROLLED release drugs , *THREE-dimensional printing , *DRUG development , *DRUG delivery systems , *PHARMACEUTICAL technology - Abstract
3D printing (3DP) is forecast to be a highly revolutionary technology within the pharmaceutical sector. In particular, the main benefits of 3DP lie in the production of small batches of medicines, each with tailored dosages, shapes, sizes and release characteristics. The manufacture of medicines in this way may finally lead to the concept of personalised medicines becoming a reality. In the shorter term, 3DP could be extended throughout the drug development process, ranging from preclinical development and clinical trials, through to frontline medical care. In this review, we provide a timely perspective on the motivations and potential applications of 3DP pharmaceuticals, as well as a practical viewpoint on how 3DP could be integrated across the pharmaceutical space. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
33. Fabricating 3D printed orally disintegrating printlets using selective laser sintering.
- Author
-
Fina, Fabrizio, Madla, Christine M., Goyanes, Alvaro, Zhang, Jiaxin, Gaisford, Simon, and Basit, Abdul W.
- Subjects
- *
SELECTIVE laser sintering , *THREE-dimensional printing , *DRUG development , *PHARMACEUTICAL powders , *ACETAMINOPHEN - Abstract
Selective laser sintering (SLS) is a three-dimensional printing (3DP) technology employed to manufacture plastic, metallic or ceramic objects. The aim of this study was to demonstrate the feasibility of using SLS to fabricate novel solid dosage forms with accelerated drug release properties, and with a view to create orally disintegrating formulations. Two polymers (hydroxypropyl methylcellulose (HPMC E5) and vinylpyrrolidone-vinyl acetate copolymer (Kollidon ® VA 64)) were separately mixed with 5% paracetamol (used as a model drug) and 3% Candurin ® Gold Sheen colorant; the powder mixes were subjected to SLS printing, resulting in the manufacture of printlets (3DP tablets). Modulating the SLS printing parameters altered the release characteristics of the printlets, with faster laser scanning speeds accelerating drug release from the HPMC formulations. The same trend was observed for the Kollidon ® based printlets. At a laser scanning speed of 300 mm/s, the Kollidon ® printlets exhibited orally disintegrating characteristics by completely dispersing in <4 s in a small volume of water. X-ray micro-CT analysis of these printlets indicated a reduction in their density and an increase in open porosity, therefore, confirming the unique disintegration behaviour of these formulations. The work reported here is the first to demonstrate the feasibility of SLS 3DP to fabricate printlets with accelerated drug release and orally disintegrating properties. This investigation has confirmed that SLS is amenable to the pharmaceutical research of modern medicine manufacture. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
34. Advancing non-destructive analysis of 3D printed medicines.
- Author
-
Jørgensen, Anna Kirstine, Ong, Jun Jie, Parhizkar, Maryam, Goyanes, Alvaro, and Basit, Abdul W.
- Subjects
- *
INDIVIDUALIZED medicine , *GENERIC drug manufacturing , *SPECTROSCOPIC imaging , *THREE-dimensional printing , *QUALITY control , *DRUGS - Abstract
3D printing of medicines holds the potential to revolutionise therapeutic regimens and manufacture by offering tuneable, personalised, and on-demand manufacture at a small scale and at the PoC. Regulatory authorities have established expert working groups and have called for stakeholder feedback to develop new, additional regulatory guidelines concerning implementation and QC for decentralised and PoC manufacturing. Recent research has demonstrated the applications of non-destructive analytical techniques (herein PATs) as measures to assess the quality of the printed therapeutics. In particular, spectroscopic and chemical imaging techniques have been highlighted. Moreover, some research has demonstrated the feasibility of implementing process control monitoring tools to assure the quality of 3D printed drug products. Pharmaceutical 3D printing (3DP) has attracted significant interest over the past decade for its ability to produce personalised medicines on demand. However, current quality control (QC) requirements for traditional large-scale pharmaceutical manufacturing are irreconcilable with the production offered by 3DP. The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) have recently published documents supporting the implementation of 3DP for point-of-care (PoC) manufacturing along with regulatory hurdles. The importance of process analytical technology (PAT) and non-destructive analytical tools in translating pharmaceutical 3DP has experienced a surge in recognition. This review seeks to highlight the most recent research on non-destructive pharmaceutical 3DP analysis, while also proposing plausible QC systems that complement the pharmaceutical 3DP workflow. In closing, outstanding challenges in integrating these analytical tools into pharmaceutical 3DP workflows are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Developing an innovative 3D printing platform for production of personalised medicines in a hospital for the OPERA clinical trial.
- Author
-
Denis, Lucas, Jørgensen, Anna Kirstine, Do, Bernard, Vaz-Luis, Inès, Pistilli, Barbara, Rieutord, André, Basit, Abdul W, Goyanes, Alvaro, and Annereau, Maxime
- Subjects
- *
THREE-dimensional printing , *INDIVIDUALIZED medicine , *CLINICAL trials , *HOSPITAL pharmacies , *MAKERSPACES , *ANTIDEPRESSANTS , *3-D printers - Abstract
[Display omitted] Breast cancer is the most frequently diagnosed cancer in women worldwide, and non-adherence to adjuvant hormonotherapy can negatively impact cancer recurrence and relapse. Non-adherence is associated with side effects of hormonotherapy. Pharmacological strategies to mitigate the side effects include coadministration of antidepressants, however patients remain non-adherent. The aim of this work was to develop medicines containing both hormonotherapy, tamoxifen (20 mg), along with anti-depressants, either venlafaxine (37.5 or 75 mg) or duloxetine (30 or 60 mg), to assess the acceptability and efficacy of this personalised approach for mitigating tamoxifen side effects in a clinical trial. A major criterion for the developed medicines was the production rate, specified at minimum 200 dosage units per hour to produce more than 40,000 units required for the clinical trial. A novel capsule filling approach enabled by the pharmaceutical 3D printer M3DIMAKER 2 was developed for this purpose. Firstly, semi-solid extrusion 3D printing enabled the filling of tamoxifen pharma-ink prepared according to French compounding regulation, followed by filling of commercial venlafaxine or duloxetine pellets enabled by the development of an innovative pellet dispensing printhead. The medicines were successfully developed and produced in the clinical pharmacy department of the cancer hospital Gustave Roussy, located in Paris, France. The developed medicines satisfied quality and production rate requirements and were stable for storage up to one year to cover the duration of the trial. This work demonstrates the feasibility of developing and producing combined tamoxifen medicines in a hospital setting through a pharmaceutical 3D printer to enable a clinical trial with a high medicines production rate requirement. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. 3D printed dispersible efavirenz tablets: A strategy for nasogastric administration in children.
- Author
-
Funk, Nadine Lysyk, Januskaite, Patricija, Beck, Ruy Carlos Ruver, Basit, Abdul W., and Goyanes, Alvaro
- Subjects
- *
EFAVIRENZ , *DOSAGE forms of drugs , *SELECTIVE laser sintering , *OFF-label use (Drugs) , *THREE-dimensional printing , *NUTRITIONAL requirements - Abstract
[Display omitted] Enteral feeding tubes (EFTs) can be placed in children diagnosed with HIV which need nutritional support due to malnutrition. EFTs are the main route for medication administration in these patients, bringing up concerns about off label use of medicines, dose inaccuracy and tube clogging. Here we report for the first time the use of selective laser sintering (SLS) 3D printing to develop efavirenz (EFZ) dispersible printlets for patients with HIV that require EFT administration. Water soluble polymers Parteck® MXP and Kollidon® VA64 were used to obtain both 500 mg (P500 and K500) and 1000 mg printlets (P1000 and K1000) containing 200 mg of EFZ each. The use of SLS 3D printing obtained porous dosage forms with high drug content (20 % and 40 % w/w) and drug amorphization using both polymers. P500, K500 and K1000 printlets reached disintegration in under 230 s in 20 mL of water (25 ± 1 °C), whilst P1000 only partially disintegrated, possibly due to saturation of the polymer in the medium. As a result, the development of dispersible EFZ printlets using hydrophilic polymers can be explored as a potential strategy for drug delivery through EFTs in paediatrics with HIV, paving the way towards the exploration of more rapidly disintegrating polymers and excipients for SLS 3D printing. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Paediatric clinical study of 3D printed personalised medicines for rare metabolic disorders.
- Author
-
Rodríguez-Pombo, Lucía, de Castro-López, María José, Sánchez-Pintos, Paula, Giraldez-Montero, Jose Maria, Januskaite, Patricija, Duran-Piñeiro, Goretti, Dolores Bóveda, M., Alvarez-Lorenzo, Carmen, Basit, Abdul W., Goyanes, Alvaro, and Couce, Maria L.
- Subjects
- *
INDIVIDUALIZED medicine , *CITRULLINE , *METABOLIC disorders , *PEACH , *PATIENT preferences , *AMINO acids , *THREE-dimensional printing - Abstract
[Display omitted] Rare diseases are infrequent, but together they affect up to 6–10 % of the world's population, mainly children. Patients require precise doses and strict adherence to avoid metabolic or cardiac failure in some cases, which cannot be addressed in a reliable way using pharmaceutical compounding. 3D printing (3DP) is a disruptive technology that allows the real-time personalization of the dose and the modulation of the dosage form to adapt the medicine to the therapeutic needs of each patient. 3D printed chewable medicines containing amino acids (citrulline, isoleucine, valine, and isoleucine and valine combinations) were prepared in a hospital setting, and the efficacy and acceptability were evaluated in comparison to conventional compounded medicines in six children. The inclusion of new flavours (lemon, vanilla and peach) to obtain more information on patient preferences and the implementation of a mobile app to obtain patient feedback in real-time was also used. The 3D printed medicines controlled amino acid levels within target levels as well as the conventional medicines. The deviation of citrulline levels was narrower and closer within the target concentration with the chewable formulations. According to participants' responses, the chewable formulations were well accepted and can improve adherence and quality of life. For the first time, 3DP enabled two actives to be combined in the same formulation, reducing the number of administrations. This study demonstrated the benefits of preparing 3D printed personalized treatments for children diagnosed with rare metabolic disorders using a novel technology in real clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Disrupting 3D printing of medicines with machine learning.
- Author
-
Elbadawi, Moe, McCoubrey, Laura E., Gavins, Francesca K.H., Ong, Jun J., Goyanes, Alvaro, Gaisford, Simon, and Basit, Abdul W.
- Subjects
- *
MACHINE learning , *ARTIFICIAL intelligence , *INDIVIDUALIZED medicine , *QUALITY control , *DRUGS , *NEW product development , *THREE-dimensional printing - Abstract
3D printing (3DP) is a progressive technology capable of transforming pharmaceutical development. However, despite its promising advantages, its transition into clinical settings remains slow. To make the vital leap to mainstream clinical practice and improve patient care, 3DP must harness modern technologies. Machine learning (ML), an influential branch of artificial intelligence, may be a key partner for 3DP. Together, 3DP and ML can utilise intelligence based on human learning to accelerate drug product development, ensure stringent quality control (QC), and inspire innovative dosage-form design. With ML's capabilities, streamlined 3DP drug delivery could mark the next era of personalised medicine. This review details how ML can be applied to elevate the 3DP of pharmaceuticals and importantly, how it can expedite 3DP's integration into mainstream healthcare. 3D printing (3DP), also known as additive manufacturing, is a fabrication technology allowing the precise fabrication of personalised drug-loaded products. 3DP has achieved various successes, including the FDA-approved drug product Spritam®. However, the new technology is underutilised, with the promise of personalised and on-demand application remaining at the proof-of-concept stage. ML has the potential to save costs and streamline the 3DP process by making accurate and rapid predictions for the key process parameters and formulation characteristics of drug-loaded products. The integration of ML with 3DP, both digitalised processes, could facilitate a transition from 'one size fits all' treatments towards data-driven omics and the manufacture of personalised medicines. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
39. Translating 3D printed pharmaceuticals: From hype to real-world clinical applications.
- Author
-
Seoane-Viaño, Iria, Trenfield, Sarah J., Basit, Abdul W., and Goyanes, Alvaro
- Subjects
- *
THREE-dimensional printing , *DRUGS , *BIOMEDICAL engineering , *DRUG development , *MEDICAL equipment - Abstract
[Display omitted] Three-dimensional (3D) printing is a revolutionary technology that is disrupting pharmaceutical development by enabling the production of personalised printlets (3D printed drug products) on demand. By creating small batches of dose flexible medicines, this versatile technology offers significant advantages for clinical practice and drug development, namely the ability to personalise medicines to individual patient needs, as well as expedite drug development timelines within preclinical studies through to first-in-human (FIH) and Phase I/II clinical trials. Despite the widely demonstrated benefits of 3D printing pharmaceuticals, the clinical potential of the technology is yet to be realised. In this timely review, we provide an overview of the latest cutting-edge investigations in 3D printing pharmaceuticals in the pre-clinical and clinical arena and offer a forward-looking approach towards strategies to further aid the translation of 3D printing into the clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. Semi-solid extrusion 3D printing in drug delivery and biomedicine: Personalised solutions for healthcare challenges.
- Author
-
Seoane-Viaño, Iria, Januskaite, Patricija, Alvarez-Lorenzo, Carmen, Basit, Abdul W., and Goyanes, Alvaro
- Subjects
- *
THREE-dimensional printing , *INDIVIDUALIZED medicine , *BIOPRINTING , *MEDICAL equipment , *MANUFACTURING processes - Abstract
Three-dimensional (3D) printing is an innovative additive manufacturing technology, capable of fabricating unique structures in a layer-by-layer manner. Semi-solid extrusion (SSE) is a subset of material extrusion 3D printing, and through the sequential deposition of layers of gel or paste creates objects of any desired size and shape. In comparison to other extrusion-based technologies, SSE 3D printing employs low printing temperatures which makes it suitable for drug delivery and biomedical applications, and the use of disposable syringes provides benefits in meeting critical quality requirements for pharmaceutical use. Besides pharmaceutical manufacturing, SSE 3D printing has attracted increasing attention in the field of bioelectronics, particularly in the manufacture of biosensors capable of measuring physiological parameters or as a means to trigger drug release from medical devices. This review begins by highlighting the major printing process parameters and material properties that influence the feasibility of transforming a 3D design into a 3D object, and follows with a discussion on the current SSE 3D printing developments and their applications in the fields of pharmaceutics, bioprinting and bioelectronics. Finally, the advantages and limitations of this technology are explored, before focusing on its potential clinical applications and suitability for preparing personalised medicines. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
41. Vat photopolymerization 3D printing for advanced drug delivery and medical device applications.
- Author
-
Xu, Xiaoyan, Awad, Atheer, Robles-Martinez, Pamela, Gaisford, Simon, Goyanes, Alvaro, and Basit, Abdul W.
- Subjects
- *
THREE-dimensional printing , *DRUG delivery devices , *PHOTOPOLYMERIZATION , *DRUG delivery systems , *MEDICAL equipment - Abstract
Three-dimensional (3D) printing is transforming manufacturing paradigms within healthcare. Vat photopolymerization 3D printing technology combines the benefits of high resolution and favourable printing speed, offering a sophisticated approach to fabricate bespoke medical devices and drug delivery systems. Herein, an overview of the vat polymerization techniques, their unique applications in the fields of drug delivery and medical device fabrication, material examples and the advantages they provide within healthcare, is provided. The challenges and drawbacks presented by this technology are also discussed. It is forecast that the adoption of 3D printing could pave the way for a personalised health system, advancing from traditional treatments pathways towards digital healthcare. Unlabelled Image [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
42. 3D printing: Principles and pharmaceutical applications of selective laser sintering.
- Author
-
Awad, Atheer, Fina, Fabrizio, Goyanes, Alvaro, Gaisford, Simon, and Basit, Abdul W.
- Subjects
- *
SELECTIVE laser sintering , *THREE-dimensional printing , *COMPUTER-aided design , *DRUG factories , *MANUFACTURED products , *DRUG delivery systems - Abstract
Pharmaceutical three-dimensional (3D) printing is a modern fabrication process with the potential to create bespoke drug products of virtually any shape and size from a computer-aided design model. Selective laser sintering (SLS) 3D printing combines the benefits of high printing precision and capability, enabling the manufacture of medicines with unique engineering and functional properties. This article reviews the current state-of-the-art in SLS 3D printing, including the main principles underpinning this technology, and highlights the diverse selection of materials and essential parameters that influence printing. The technical challenges and processing conditions are also considered in the context of their effects on the printed product. Finally, the pharmaceutical applications of SLS 3D printing are covered, providing an emphasis on the advantages the technology offers to drug product manufacturing and personalised medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
43. Non-destructive dose verification of two drugs within 3D printed polyprintlets.
- Author
-
Trenfield, Sarah J., Tan, Hui Xian, Goyanes, Alvaro, Wilsdon, David, Rowland, Martin, Gaisford, Simon, and Basit, Abdul W.
- Subjects
- *
THREE-dimensional printing , *X-ray powder diffraction , *DRUG dosage , *3-D films , *SELECTIVE laser sintering - Abstract
Three-dimensional printing (3DP) is a revolutionary technology in pharmaceuticals, enabling the personalisation of flexible-dose drug products and 3D printed polypills (polyprintlets). A major barrier to entry of this technology is the lack of non-destructive quality control methods capable of verifying the dosage of multiple drugs in polyprintlets at the point of dispensing. In the present study, 3D printed films and cylindrical polyprintlets were loaded with flexible, therapeutic dosages of two distinct drugs (amlodipine and lisinopril) across concentration ranges of 1–5% w/w and 2–10% w/w , respectively. The polyprintlets were non-destructively analysed for dose content using a portable near infrared (NIR) spectrometer and validated calibration models were developed using partial least squares (PLS) regression, which showed excellent linearity (R2 Pred = 0.997, 0.991), accuracy (RMSEP = 0.24%, 0.24%) and specificity (LV1 = 82.77%, 79.55%) for amlodipine and lisinopril, respectively. X-ray powder diffraction (XRPD) and thermogravimetric analysis (TGA) showed that sintering partially transformed the phase of both drugs from the crystalline to amorphous forms. For the first time, we report a non-destructive method for quality control of two separate active ingredients in a single 3D printed drug product using NIR spectroscopy, overcoming a major barrier to the integration of 3D printing into clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
44. Supramolecular chemistry enables vat photopolymerization 3D printing of novel water-soluble tablets.
- Author
-
Ong, Jun Jie, Chow, Yee Lam, Gaisford, Simon, Cook, Michael T., Swift, Thomas, Telford, Richard, Rimmer, Stephen, Qin, Yujia, Mai, Yang, Goyanes, Alvaro, and Basit, Abdul W.
- Subjects
- *
SUPRAMOLECULAR chemistry , *POLYMERS , *PHOTOPOLYMERIZATION , *THREE-dimensional printing , *ACUTE toxicity testing , *SUPRAMOLECULAR polymers , *MOLECULAR weights - Abstract
[Display omitted] Vat photopolymerization has garnered interest from pharmaceutical researchers for the fabrication of personalised medicines, especially for drugs that require high precision dosing or are heat labile. However, the 3D printed structures created thus far have been insoluble, limiting printable dosage forms to sustained-release systems or drug-eluting medical devices which do not require dissolution of the printed matrix. Resins that produce water-soluble structures will enable more versatile drug release profiles and expand potential applications. To achieve this, instead of employing cross-linking chemistry to fabricate matrices, supramolecular chemistry may be used to impart dynamic interaction between polymer chains. In this study, water-soluble drug-loaded printlets (3D printed tablets) are fabricated via digital light processing (DLP) 3DP for the first time. Six formulations with varying ratios of an electrolyte acrylate monomer, [2-(acryloyloxy)ethyl]trimethylammonium chloride (TMAEA), and a co-monomer, 1-vinyl-2-pyrrolidone (NVP), were prepared to produce paracetamol-loaded printlets. 1H NMR spectroscopy analysis confirmed the integration of TMAEA and NVP in the polymer, and residual TMAEA monomers were found to be present only in trace amounts (0.71 – 1.37 %w/w). The apparent molecular mass of the photopolymerised polymer was found to exceed 300,000 Da with hydrodynamic radii of 15 – 20 nm, estimated based on 1H DOSY NMR measurements The loaded paracetamol was completely released from the printlets between 45 minutes to 5 hours. In vivo single-dose acute toxicity studies in rats suggest that the printlets did not cause any tissue damage. The findings reported in this study represent a significant step towards the adoption of vat photopolymerization-based 3DP to produce personalised medicines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
45. Low temperature fused deposition modeling (FDM) 3D printing of thermolabile drugs.
- Author
-
Kollamaram, Gayathri, Croker, Denise M., Walker, Gavin M., Goyanes, Alvaro, Basit, Abdul W., and Gaisford, Simon
- Subjects
- *
FUSED deposition modeling , *THREE-dimensional printing , *INDIVIDUALIZED medicine , *MELTING points , *NUCLEAR magnetic resonance spectroscopy - Abstract
Fused deposition modelling (FDM) is the most commonly investigated 3D printing technology for the manufacture of personalized medicines, however, the high temperatures used in the process limit its wider application. The objective of this study was to print low-melting and thermolabile drugs by reducing the FDM printing temperature. Two immediate release polymers, Kollidon VA64 and Kollidon 12PF were investigated as potential candidates for low-temperature FDM printing. Ramipril was used as the model low melting temperature drug (109 °C); to the authors’ knowledge this is the lowest melting point drug investigated to date by FDM printing. Filaments loaded with 3% drug were obtained by hot melt extrusion at 70 °C and ramipril printlets with a dose equivalent of 8.8 mg were printed at 90 °C. HPLC analysis confirmed that the drug was stable with no signs of degradation and dissolution studies revealed that drug release from the printlets reached 100% within 20–30 min. Variable temperature Raman and solid state nuclear magnetic resonance (SSNMR) spectroscopy techniques were used to evaluate drug stability over the processing temperature range. These data indicated that ramipril did not undergo degradation below its melting point (which is above the processing temperature range: 70–90 °C) but it was transformed into the impurity diketopiperazine upon exposure to temperatures higher than its melting point. The use of the excipients Kollidon VA64 and Kollidon 12PF in FDM was further validated by printing with the drug 4-aminosalicylic acid (4-ASA), which in previous work was reported to undergo degradation in FDM printing, but here it was found to be stable. This work demonstrates that the selection and use of new excipients can overcome one of the major disadvantages in FDM printing, drug degradation due to thermal heating, making this technology suitable for drugs with lower melting temperatures. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
46. A customizable 3D printed device for enzymatic removal of drugs in water.
- Author
-
Xu, Xiaoyan, Pose-Boirazian, Tomás, Eibes, Gemma, McCoubrey, Laura E., Martínez-Costas, Jose, Gaisford, Simon, Goyanes, Alvaro, and Basit, Abdul W.
- Subjects
- *
DRUG pollution of water , *ETHINYL estradiol , *ENVIRONMENTAL risk , *WATER pollution , *ETHYLENE glycol , *THREE-dimensional printing , *LACCASE - Abstract
• A 3D printed biocatalytic device (termed Printzyme) is proposed for enzymatic removal of drugs from water. • Laccase was immobilised within a poly(ethylene glycol) diacrylate hydrogel using stereolithography 3D printing. • The Printzyme is customizable, highly reusable, and cost-efficient. • 95% of diclofenac and ethinylestradiol from aqueous solution were removed within 24 and 2 h, respectively. The infiltration of drugs into water is a key global issue, with pharmaceuticals being detected in all nearly aqueous systems at often alarming concentrations. Pharmaceutical contamination of environmental water supplies has been shown to negatively impact ecological equilibrium and pose a risk to human health. In this study, we design and develop a novel system for the removal of drugs from water, termed as Printzyme. The device, fabricated with stereolithography (SLA) 3D printing, immobilises laccase sourced from Trametes Versicolor within a poly(ethylene glycol) diacrylate hydrogel. We show that SLA printing is a sustainable method for enzyme entrapment under mild conditions, and measure the stability of the system when exposed to extremes of pH and temperature in comparison to free laccase. When tested for its drug removal capacity, the 3D printed device substantially degraded two dissolved drugs on the European water pollution watch list. When configured in the shape of a torus, the device effectively removed 95% of diclofenac and ethinylestradiol from aqueous solution within 24 and 2 h, respectively, more efficiently than free enzyme. Being customizable and reusable, these 3D printed devices could help to efficiently tackle the world's water pollution crisis, in a flexible, easily scalable, and cost-efficient manner. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
47. Smartphone-enabled 3D printing of medicines.
- Author
-
Xu, Xiaoyan, Seijo-Rabina, Alejandro, Awad, Atheer, Rial, Carlos, Gaisford, Simon, Basit, Abdul W., and Goyanes, Alvaro
- Subjects
- *
THREE-dimensional printing , *3-D printers , *SMARTPHONES , *POINT-of-care testing , *TORUS - Abstract
[Display omitted] 3D printing is a manufacturing technique that is transforming numerous industrial sectors, particularly where it is key tool in the development and fabrication of medicinees that are personalised to the individual needs of patients. Most 3D printers are relatively large, require trained operators and must be located in a pharmaceutical setting to manufacture dosage forms. In order to realise fully the potential of point-of-care manufacturing of medicines, portable printers that are easy to operate are required. Here, we report the development of a 3D printer that operates using a mobile smartphone. The printer, operating on stereolithographic principles, uses the light from the smartphone's screen to photopolymerise liquid resins and create solid structures. The shape of the printed dosage form is determined using a custom app on the smartphone. Warfarin-loaded Printlets (3D printed tablets) of various sizes and patient-centred shapes (caplet, triangle, diamond, square, pentagon, torus, and gyroid lattices) were successfully printed to a high resolution and with excellent dimensional precision using different photosensitive resins. The drug was present in an amorphous form, and the Printlets displayed sustained release characterises. The promising proof-of-concept results support the future potential of this compact, user-friendly and interconnected smartphone-based system for point-of-care manufacturing of personalised medications. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
48. Anti-biofilm multi drug-loaded 3D printed hearing aids.
- Author
-
Vivero-Lopez, María, Xu, Xiaoyan, Muras, Andrea, Otero, Ana, Concheiro, Angel, Gaisford, Simon, Basit, Abdul W., Alvarez-Lorenzo, Carmen, and Goyanes, Alvaro
- Subjects
- *
HEARING aids , *ASSISTIVE listening systems , *CONTROLLED release drugs , *HEARING disorders , *MEDICAL equipment , *THREE-dimensional printing - Abstract
Over 5% of the world's population has disabling hearing loss, which affects approximately one third of individuals over 65 years. Hearing aids are commonly used in this population group, but prolonged use of these devices may cause ear infections. We describe for the first time, the use of 3D printing to fabricate hearing aids loaded with two antibiotics, ciprofloxacin and fluocinolone acetonide. Digital light processing 3D printing was employed to manufacture hearing aids from two polymer resins, ENG hard and Flexible. The inclusion of the antibiotics did not affect the mechanical properties of the hearing aids. All multi-drug-loaded devices exhibited a hydrophilic surface, excellent blood compatibility and anti-biofilm activity against P. aeruginosa and S. aureus. Hearing aids loaded with ciprofloxacin (6% w/w) and fluocinolone acetonide (0.5% w/w) sustained drug release for more than two weeks and inhibited biofilm formation on the surface of the devices and bacteria growth in the surrounding medium. In summary, this work highlights the potential of vat photopolymerization 3D printing as a versatile manufacturing approach to fabricate high-fidelity patient-specific medical devices with anti-bacterial properties. Unlabelled Image • Digital light processing 3D printing was used to prepare multi drug-loaded hearing aids. • The fabricated devices where mechanically robust, non-toxic, and exhibited a hydrophilic surface. • The devices provided prolonged release of antibiotics for more than two weeks. • All drug-loaded devices demonstrated anti-biofilm activity against P. aeruginosa and S. aureus. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. M3DISEEN: A novel machine learning approach for predicting the 3D printability of medicines.
- Author
-
Elbadawi, Moe, Muñiz Castro, Brais, Gavins, Francesca K.H., Ong, Jun Jie, Gaisford, Simon, Pérez, Gilberto, Basit, Abdul W., Cabalar, Pedro, and Goyanes, Alvaro
- Subjects
- *
MACHINE learning , *FUSED deposition modeling , *MELT spinning , *THREE-dimensional printing , *ARTIFICIAL intelligence - Abstract
Artificial intelligence (AI) has the potential to reshape pharmaceutical formulation development through its ability to analyze and continuously monitor large datasets. Fused deposition modeling (FDM) three-dimensional printing (3DP) has made significant advancements in the field of oral drug delivery with personalized drug-loaded formulations being designed, developed and dispensed for the needs of the patient. The FDM 3DP process begins with the production of drug-loaded filaments by hot melt extrusion (HME), followed by the printing of a drug product using a FDM 3D printer. However, the optimization of the fabrication parameters is a time-consuming, empirical trial approach, requiring expert knowledge. Here, M3DISEEN, a web-based pharmaceutical software, was developed to accelerate FDM 3D printing using AI machine learning techniques (MLTs). In total, 614 drug-loaded formulations were designed from a comprehensive list of 145 different pharmaceutical excipients, 3D printed and assessed in-house. To build the predictive tool, a dataset was constructed and models were trained and tested at a ratio of 75:25. Significantly, the AI models predicted key fabrication parameters with accuracies of 76% and 67% for the printability and the filament characteristics, respectively. Furthermore, the AI models predicted the HME and FDM processing temperatures with a mean absolute error of 8.9 °C and 8.3 °C, respectively. Strikingly, the AI models achieved high levels of accuracy by solely inputting the pharmaceutical excipient trade names. Therefore, AI provides an effective holistic modeling technology and software to streamline and advance 3DP as a significant technology within drug development. M3DISEEN is available at (http://m3diseen.com/predictions/). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
50. 3D printed opioid medicines with alcohol-resistant and abuse-deterrent properties.
- Author
-
Ong, Jun Jie, Awad, Atheer, Martorana, Annalisa, Gaisford, Simon, Stoyanov, Edmont, Basit, Abdul W., and Goyanes, Alvaro
- Subjects
- *
NALTREXONE , *POLYETHYLENE oxide , *OPIOID abuse , *FENTANYL , *SOLVENT extraction , *THREE-dimensional printing , *DRUGS - Abstract
In the past decade, prescriptions for opioid medicines have been exponentially increasing, instigating opioid abuse as a global health crisis associated with high morbidity and mortality. In particular, diversion from the intended mode of opioid administration, such as injecting and snorting the opioid, is a major problem that contributes to this epidemic. In light of this, novel formulation strategies are needed to support efforts in reducing the prevalence and risks of opioid abuse. Here, modified release tramadol printlets (3D printed tablets) with alcohol-resistant and abuse-deterrent properties were prepared by direct powder extrusion three-dimensional (3D) printing. The printlets were fabricated using two grades of hydroxypropylcellulose (HPC). Both formulations displayed strong ethanol-resistance and had moderate abuse-deterrent properties. Polyethylene oxide (PEO) was subsequently added into the formulations, which improved the printlets' resistance to physical tampering in nasal inhalation tests and delayed their dissolution in solvent extraction tests. Overall, this article reports for the first time the use of direct powder extrusion 3D printing to prepare drug products with both alcohol-resistant and abuse-deterrent properties. These results offer a novel approach for the safe and effective use of opioids that can contribute to the advantages that 3D printing provides in terms of on-demand dose personalisation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.